TMCnet News
ICPT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Intercept Pharmaceuticals, Inc.The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ:ICPT) violated federal securities laws. Click here to learn about the case: http://docs.wongesq.com/ICPT-Info-Request-Form-1712. There is no cost or obligation to you. On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva (obeticholic acid), the Company's treatment for primary biliary cholangitis ("PBC"), advising them thatthe drug has been tied to liver injuries and death among patients suffering from PBC. Then on September 21, 2017, the Food and Drug Administration issued a Safety Announcement that the drug "is being incorrectly dosed in some patients…resulting in an increased risk of serious liver injury and death." The FDA noted that "In the 13 months after Ocaliva was approved in May 2016, FDA received reports of serious liver injury or death associated with Ocaliva." To learn more about the investigation of Intercept contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/ICPT-Info-Request-Form-1712. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171018006192/en/ |
